CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 80 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $35,000 | +59.1% | 17,681 | 0.0% | 0.00% | – |
| Q4 2020 | $22,000 | -70.7% | 17,681 | -57.5% | 0.00% | – |
| Q3 2020 | $75,000 | -84.3% | 41,598 | -27.1% | 0.00% | -100.0% |
| Q2 2020 | $479,000 | +131.4% | 57,098 | +44.2% | 0.00% | – |
| Q1 2020 | $207,000 | -38.4% | 39,598 | -35.7% | 0.00% | – |
| Q4 2019 | $336,000 | +6.3% | 61,598 | -4.9% | 0.00% | – |
| Q3 2019 | $316,000 | -44.9% | 64,798 | -21.8% | 0.00% | -100.0% |
| Q2 2019 | $574,000 | +24.0% | 82,824 | +24.4% | 0.00% | 0.0% |
| Q1 2019 | $463,000 | +3.6% | 66,579 | -13.0% | 0.00% | 0.0% |
| Q4 2018 | $447,000 | +42.4% | 76,494 | +84.1% | 0.00% | – |
| Q3 2018 | $314,000 | +234.0% | 41,543 | +123.4% | 0.00% | – |
| Q2 2018 | $94,000 | -3.1% | 18,598 | +17.1% | 0.00% | – |
| Q1 2018 | $97,000 | -90.7% | 15,885 | -87.4% | 0.00% | -100.0% |
| Q1 2017 | $1,038,000 | -12.0% | 125,830 | -9.9% | 0.00% | -33.3% |
| Q4 2016 | $1,180,000 | +671.2% | 139,680 | +65.4% | 0.00% | +200.0% |
| Q1 2016 | $153,000 | – | 84,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 397,168 | $43,888 | 0.01% |
| CJM Wealth Advisers, Ltd. | 30,465 | $3,366 | 0.00% |
| Tekla Capital Management LLC | 154,310 | $17,051 | 0.00% |
| McAdam, LLC | 10,006 | $6 | 0.00% |
| Aries Wealth Management | 15,400 | $1,702 | 0.00% |
| WELLS FARGO & COMPANY/MN | 342,084 | $37,800 | 0.00% |
| JPMORGAN CHASE & CO | 43,415 | $5 | 0.00% |
| NORTHERN TRUST CORP | 207,329 | $22,910 | 0.00% |
| PINNACLE ASSOCIATES LTD | 18,580 | $2,053 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |